IOVA stock forecast, quote, news & analysis
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient... Show more
Why Iovance Biotherapeutics (IOVA) Is Down -8% in the Last 30 Days
Key Takeaways
- IOVA stock declined approximately -8% over the past 30 days amid post-earnings profit-taking and sector headwinds, trading from around $3.75 to $3.46.
- Over the past quarter, shares surged +38%, rising from about $2.50 to $3.46, fueled by strong Q4 2025 earnings and Amtagvi commercial momentum.
- Key drivers include robust revenue growth from FDA-approved Amtagvi (lifileucel), offset recently by manufacturing concerns and competitive pressures in biotech.
- Analyst sentiment remains positive with targets up to $16, highlighting long-term TIL therapy potential.
- Upcoming Q1 2026 earnings in May will be pivotal for assessing Amtagvi ramp-up.
Iovance Biotherapeutics (IOVA) Company Overview and Market Position
Iovance Biotherapeutics, Inc. (IOVA) is a clinical-stage biotechnology company specializing in tumor-infiltrating lymphocyte (TIL) therapies to treat solid tumor cancers. Its lead product, Amtagvi (lifileucel), is the first FDA-approved (Food and Drug Administration) TIL therapy for advanced melanoma, marking a breakthrough in personalized cell therapies. The company's business model focuses on developing and commercializing autologous TIL therapies, leveraging patient-specific tumor cells to create targeted immune responses. In the competitive biotech landscape, Iovance holds a pioneering position in TIL technology for solid tumors, differentiating it from CAR-T therapies primarily used in blood cancers. Strong fundamentals, including expanding Amtagvi sales, underpin recent price resilience despite volatility typical in biotech stock analysis.
Iovance Biotherapeutics (IOVA) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, IOVA stock has fallen -8%, moving from approximately $3.75 to $3.46 in a volatile, range-bound pattern amid profit-taking. The decline reflects choppy trading, with shares fluctuating between $3.40 and $3.80.
In contrast, the past quarter saw a robust +38% gain, climbing from around $2.50 (near January 23 close of $2.64) to $3.46, driven by a steady uptrend post-earnings. This period featured heightened volume and momentum, though with intermittent pullbacks characteristic of biotech market trends.
What Drove IOVA Stock Price in the Last 30 Days
The -8% drop in IOVA's stock price over the past 30 days stemmed primarily from post-earnings digestion following strong Q4 2025 results reported in late February/early March. Shares fell 2.1% since the March 26 earnings release, as investors locked in gains after a multi-month rally. A recent 8% single-day plunge was triggered by negative sentiment around competitor Replimune's data, raising concerns over sector competition for TIL therapies. Broader biotech pressures, including manufacturing hiccups and slower-than-expected authorized treatment center (ATC) ramp-up for Amtagvi, contributed to the pullback. High short interest at 31.5% amplified volatility.
What Drove IOVA Stock Performance Over the Last Quarter
The +38% quarterly advance was propelled by blockbuster Q4 2025 earnings, with Amtagvi delivering 30% revenue growth to ~$65 million, signaling successful commercial launch. Positive clinical trial results for tissue cancer treatments and analyst upgrades (targets $12-$16) boosted confidence. Institutional buying and biotech sector recovery amid favorable macro conditions, like stabilizing interest rates, supported the uptrend. Cumulative impact from Amtagvi's traction overshadowed competition risks.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the top-performing AI trading bots from its extensive library of hundreds of algorithms scanning thousands of tickers. These curated bots highlight those with the strongest recent returns, varying by strategy—such as trend-following, mean reversion, or momentum—and timeframes from intraday to long-term. Performance metrics like win rate, Sharpe ratio, and max drawdown provide transparency for users. Ideal for stock analysis enthusiasts, the page updates dynamically to feature the most relevant bots amid current market trends. Explore Trending AI Robots to integrate cutting-edge AI into your trading strategy.
IOVA Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor Q1 2026 earnings around May 7-14 for Amtagvi sales updates and ATC expansion progress. Pipeline advancements in new indications, like non-small cell lung cancer, and partnerships could catalyze sentiment. Macro factors, including interest rates and biotech funding environment, remain influential. Risks encompass manufacturing scalability, regulatory hurdles, and competition from emerging TIL players. Positive trial data or gross margin improvements may drive upside.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
IOVA in downward trend: price may decline as a result of having broken its higher Bollinger Band on May 27, 2026
IOVA broke above its upper Bollinger Band on May 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 35 similar instances where the stock broke above the upper band. In of the 35 cases the stock fell afterwards. This puts the odds of success at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for IOVA moved out of overbought territory on May 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 55 cases where IOVA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IOVA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on May 21, 2026. You may want to consider a long position or call options on IOVA as a result. In of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for IOVA just turned positive on May 22, 2026. Looking at past instances where IOVA's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
IOVA moved above its 50-day moving average on May 21, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for IOVA crossed bullishly above the 50-day moving average on May 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where IOVA advanced for three days, in of 254 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 152 cases where IOVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IOVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.348) is normal, around the industry mean (21.436). P/E Ratio (0.000) is within average values for comparable stocks, (35.703). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.661). IOVA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.039). P/S Ratio (5.066) is also within normal values, averaging (362.696).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IOVA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biotechnological products for the treatment of cancer
Industry Biotechnology